A Case with in Situ Carcinoma of the Pancreas and Intraductal Papillary-Mucinous Tumors

We report a case with in situ carcinoma of the pancreas (CIS) and intraductal papillary-mucinous tumors (IPMTs). A 68-year-old man was found in abdominal CT on admission to have acute pancreatitis with dilation of the main pancreatic duct at the body and tail of the pancreas and local inflammation h...

Full description

Saved in:
Bibliographic Details
Published inNippon Shokaki Geka Gakkai zasshi Vol. 37; no. 5; pp. 573 - 577
Main Authors Kawasaki, Motomi, Nakagawara, Hisatoshi, Okada, Shouichi, Ueda, Nobuhiko, Konishi, Fumio, Uwafuji, Seiko, Yoshimitu, Yutaka, Furuya, Hajime, Sawa, Toshiharu
Format Journal Article
LanguageJapanese
Published The Japanese Society of Gastroenterological Surgery 2004
Subjects
Online AccessGet full text
ISSN0386-9768
1348-9372
DOI10.5833/jjgs.37.573

Cover

More Information
Summary:We report a case with in situ carcinoma of the pancreas (CIS) and intraductal papillary-mucinous tumors (IPMTs). A 68-year-old man was found in abdominal CT on admission to have acute pancreatitis with dilation of the main pancreatic duct at the body and tail of the pancreas and local inflammation had no recognizable mass at the head or body even after inflammation was reduced. ERP showed stenosis of the main pancreatic duct at the body of the pancreas and slight dilation at the tail, but inadequate representation of branches. Cytology of the pancreatic juice was class IV, so we conducted pancreatectomy of the body and tail and splenectomy with D1 lymph node dissection. Pathological findings showed fibrous thickening of the main pancreatic duct at the stenotic portion and atrophy of the acinus around the duct. Although the epithelium of the main pancreatic duct at the stenotic portion was CIS, the epithelium at the tail of the stenotic portion showed intraductal papillary-mucinous adenoma with moderate dysplasia. Most epithelium of branches at the tail of the stenotic portion had IPMTs with dysplasia and part of the epithelimu was CIS. The patient has been followed up for 7 months without evidence of recurrence.
ISSN:0386-9768
1348-9372
DOI:10.5833/jjgs.37.573